



Clinical trial results:

Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2005-002965-35 |
| Trial protocol | FI |
| Global end of trial date | 02 January 2006 |

Results information

| | |
|--------------------------------|---|
| Result version number | v2 (current) |
| This version publication date | 20 November 2018 |
| First version publication date | 03 December 2014 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data setUpdate of primary account owner and back up |

Trial information

Trial identification

| | |
|-----------------------|-------|
| Sponsor protocol code | GID18 |
|-----------------------|-------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Sanofi Pasteur SA |
| Sponsor organisation address | 2, Avenue Pont Pasteur, Lyon Cedex 07, France, F-69367 |
| Public contact | Director, Clinical Development, Sanofi Pasteur SA, 33 (0)4 37 37 58 50, stephanie.pepin@sanofipasteur.com |
| Scientific contact | Director, Clinical Development, Sanofi Pasteur SA, 33 (0)4 37 37 58 50, stephanie.pepin@sanofipasteur.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 25 September 2006 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 02 January 2006 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To describe the safety of the 9 µg formulation of the inactivated, split-virion influenza vaccine administered by the intradermal (ID) route in children aged 6 to 35 months and 3 to 8 years.

Protection of trial subjects:

Only subjects that met all of the study inclusion and none of the exclusion criteria were randomized and vaccinated in the study. Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment were also available on site in case of any immediate allergic reactions.

Background therapy:

Not applicable.

Evidence for comparator:

Not applicable.

| | |
|---|-------------------|
| Actual start date of recruitment | 26 September 2005 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------|
| Country: Number of subjects enrolled | Finland: 100 |
| Worldwide total number of subjects | 100 |
| EEA total number of subjects | 100 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 38 |
| Children (2-11 years) | 62 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |

| | |
|---------------------|---|
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Study subjects were enrolled from 26 September 2005 to 28 October 2005 in 3 clinic centers in Finland.

Pre-assignment

Screening details:

A total of 100 subjects who met all of the inclusion criteria and none of the exclusion criteria were enrolled and vaccinated.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Blinding implementation details:

Not applicable

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|--------------------------|
| Arm title | ID Group (Age 3–8 years) |
|------------------|--------------------------|

Arm description:

Subjects aged 3 to 8 years at enrollment who received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | Inactivated, split-virion influenza vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intradermal use |

Dosage and administration details:

0.1 mL, intradermal into the upper arm (deltoid area), one dose each at Day 0 and Day 28

| | |
|------------------|--------------------------|
| Arm title | IM Group (Age 3–8 years) |
|------------------|--------------------------|

Arm description:

Subjects aged 3 to 8 years at enrollment who received 2 intramuscular (IM) doses of the 15 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Inactivated, split-virion influenza vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

0.5 mL, intramuscular in the deltoid muscle of subjects >1 years of age, one dose each at Day 0 and Day 28

| | |
|------------------|----------------------------|
| Arm title | ID Group (Age 6–35 months) |
|------------------|----------------------------|

Arm description:

Subjects age 6 to 35 months at enrollment who received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|---|
| Investigational medicinal product name | Inactivated, split-virion influenza vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intradermal use |
| Dosage and administration details: | |
| 0.1 mL, intradermal into the upper arm (deltoid area), one dose each at Day 0 and Day 28 | |
| Arm title | IM Group (Age 6-35 months) |

Arm description:

Subjects age 6 to 35 months at enrollment who received 2 intramuscular (IM) doses of the 7.5 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Inactivated, split-virion influenza vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

0.25 mL, intramuscular in the deltoid muscle of subjects >1 years of age and in the anterolateral aspect of the thigh in subjects <1 years of age, one dose each at Day 0 and Day 28.

| Number of subjects in period 1 | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6-35 months) |
|---------------------------------------|--------------------------|--------------------------|----------------------------|
| Started | 30 | 20 | 30 |
| Completed | 30 | 20 | 29 |
| Not completed | 0 | 0 | 1 |
| Consent withdrawn by subject | - | - | 1 |

| Number of subjects in period 1 | IM Group (Age 6-35 months) |
|---------------------------------------|----------------------------|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
| Consent withdrawn by subject | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|--------------------------|
| Reporting group title | ID Group (Age 3–8 years) |
|-----------------------|--------------------------|

Reporting group description:

Subjects aged 3 to 8 years at enrollment who received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|-----------------------|--------------------------|
| Reporting group title | IM Group (Age 3–8 years) |
|-----------------------|--------------------------|

Reporting group description:

Subjects aged 3 to 8 years at enrollment who received 2 intramuscular (IM) doses of the 15 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|-----------------------|----------------------------|
| Reporting group title | ID Group (Age 6-35 months) |
|-----------------------|----------------------------|

Reporting group description:

Subjects age 6 to 35 months at enrollment who received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| | |
|-----------------------|----------------------------|
| Reporting group title | IM Group (Age 6-35 months) |
|-----------------------|----------------------------|

Reporting group description:

Subjects age 6 to 35 months at enrollment who received 2 intramuscular (IM) doses of the 7.5 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28.

| Reporting group values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6-35 months) |
|--|--------------------------|--------------------------|----------------------------|
| Number of subjects | 30 | 20 | 30 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 24 |
| Children (2-11 years) | 30 | 20 | 6 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | 58.8 | 49.2 | 13.8 |
| standard deviation | ± 1.61 | ± 1.04 | ± 7.35 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 10 | 10 | 17 |
| Male | 20 | 10 | 13 |

| Reporting group values | IM Group (Age 6-35 months) | Total | |
|------------------------|----------------------------|-------|--|
| Number of subjects | 20 | 100 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |

| | | | |
|---|--------|----|--|
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 14 | 38 | |
| Children (2-11 years) | 6 | 62 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 0 | 0 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | 15.6 | | |
| standard deviation | ± 8.32 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 12 | 49 | |
| Male | 8 | 51 | |

End points

End points reporting groups

| | |
|--|----------------------------|
| Reporting group title | ID Group (Age 3–8 years) |
| Reporting group description: Subjects aged 3 to 8 years at enrollment who received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28. | |
| Reporting group title | IM Group (Age 3–8 years) |
| Reporting group description: Subjects aged 3 to 8 years at enrollment who received 2 intramuscular (IM) doses of the 15 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28. | |
| Reporting group title | ID Group (Age 6-35 months) |
| Reporting group description: Subjects age 6 to 35 months at enrollment who received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28. | |
| Reporting group title | IM Group (Age 6-35 months) |
| Reporting group description: Subjects age 6 to 35 months at enrollment who received 2 intramuscular (IM) doses of the 7.5 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28. | |

Primary: Percentage of Subjects Reporting Solicited Injection Site or Systemic Reaction Following Any Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|--|--|
| End point title | Percentage of Subjects Reporting Solicited Injection Site or Systemic Reaction Following Any Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route ^[1] |
| End point description: Solicited injection site reactions (children 3–8 years): Pain, Erythema, Edema, and Induration. Solicited systemic reactions (children 3–8 years): Fever, Headache, Malaise, and Myalgia. Solicited injection site reactions (infants 6–35 months): Tenderness, Erythema, Swelling, and Induration. Solicited systemic reactions (infants 6–35 months): Fever, Vomiting, Abnormal crying, Drowsiness, Appetite loss, and Irritability. | |
| End point type | Primary |
| End point timeframe: Day 0 (pre-each vaccination) up to 7 days post-each vaccination | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6-35 months) | IM Group (Age 6-35 months) |
|-------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Injection site Pain | 63.3 | 65 | 0 | 0 |
| Injection site Erythema | 90 | 35 | 80 | 25 |
| Injection site Edema | 56.7 | 10 | 0 | 0 |
| Injection site Induration | 46.7 | 30 | 53.3 | 15 |
| Fever | 3.3 | 20 | 26.7 | 50 |

| | | | | |
|---------------------------|------|----|------|----|
| Headache | 10 | 10 | 0 | 0 |
| Malaise | 13.3 | 20 | 0 | 0 |
| Myalgia | 3.3 | 10 | 0 | 0 |
| Injection site Tenderness | 0 | 0 | 43.3 | 20 |
| Injection site Swelling | 0 | 0 | 23.3 | 15 |
| Vomiting | 0 | 0 | 13.3 | 5 |
| Abnormal crying | 0 | 0 | 53.3 | 30 |
| Drowsiness | 0 | 0 | 43.3 | 15 |
| Appetite loss | 0 | 0 | 50 | 35 |
| Irritability | 0 | 0 | 63.3 | 60 |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Solicited Injection Site or Systemic Reactions Within Seven Days Following the First Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|-----------------|---|
| End point title | Percentage of Subjects Reporting Solicited Injection Site or Systemic Reactions Within Seven Days Following the First Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route ^[2] |
|-----------------|---|

End point description:

Solicited injection site reactions (children 3–8 years): Pain, Erythema, Edema, and Induration. Solicited systemic reactions (children 3–8 years): Fever, Headache, Malaise, and Myalgia. Solicited injection site reactions (infants 6–35 months): Tenderness, Erythema, Swelling, and Induration. Solicited systemic reactions (infants 6–35 months): Fever, Vomiting, Abnormal crying, Drowsiness, Appetite loss, and Irritability.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 0 (pre-vaccination) up to 7 days post-first vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6–35 months) | IM Group (Age 6–35 months) |
|-------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Injection site Pain | 53.3 | 45 | 0 | 0 |
| Injection site Erythema | 66.7 | 20 | 53.3 | 10 |
| Injection site Edema | 26.7 | 10 | 0 | 0 |
| Injection site Induration | 23.3 | 20 | 13.3 | 5 |
| Fever | 3.3 | 10 | 23.3 | 40 |
| Headache | 6.7 | 10 | 0 | 0 |
| Malaise | 6.7 | 20 | 0 | 0 |
| Myalgia | 3.3 | 10 | 0 | 0 |
| Injection site Tenderness | 0 | 0 | 23.3 | 15 |
| Injection site Swelling | 0 | 0 | 10 | 5 |

| | | | | |
|-----------------|---|---|------|----|
| Vomiting | 0 | 0 | 6.7 | 0 |
| Abnormal crying | 0 | 0 | 33.3 | 15 |
| Drowsiness | 0 | 0 | 26.7 | 15 |
| Appetite loss | 0 | 0 | 40 | 25 |
| Irritability | 0 | 0 | 46.7 | 50 |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Solicited Injection Site or Systemic Reaction Within Seven Days Following the Second Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|-----------------|---|
| End point title | Percentage of Subjects Reporting Solicited Injection Site or Systemic Reaction Within Seven Days Following the Second Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route ^[3] |
|-----------------|---|

End point description:

Solicited injection site reactions (children 3–8 years): Pain, Erythema, Edema, and Induration. Solicited systemic reactions (children 3–8 years): Fever, Headache, Malaise, and Myalgia. Solicited injection site reactions (infants 6–35 months): Tenderness, Erythema, Swelling, and Induration. Solicited systemic reactions (infants 6–35 months): Fever, Vomiting, Abnormal crying, Drowsiness, Appetite loss, and Irritability.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 0 (pre-vaccination) up to 7 days post-second vaccination

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6–35 months) | IM Group (Age 6–35 months) |
|-------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Injection site Pain | 53.3 | 45 | 0 | 0 |
| Injection site Erythema | 80 | 25 | 80 | 20 |
| Injection site Edema | 43.3 | 5 | 0 | 0 |
| Injection site Induration | 40 | 20 | 50 | 10 |
| Fever | 0 | 10 | 13.3 | 30 |
| Headache | 3.3 | 0 | 0 | 0 |
| Malaise | 6.7 | 5 | 0 | 0 |
| Myalgia | 0 | 5 | 0 | 0 |
| Injection site Tenderness | 0 | 0 | 43.3 | 10 |
| Injection site Swelling | 0 | 0 | 23.3 | 15 |
| Vomiting | 0 | 0 | 13.3 | 5 |
| Abnormal crying | 0 | 0 | 26.7 | 15 |
| Drowsiness | 0 | 0 | 23.3 | 5 |
| Appetite loss | 0 | 0 | 26.7 | 25 |

| | | | | |
|--------------|---|---|----|----|
| Irritability | 0 | 0 | 40 | 45 |
|--------------|---|---|----|----|

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titers (GMTs) of influenza Vaccine Antibodies Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|------------------------|--|
| End point title | Geometric Mean Titers (GMTs) of influenza Vaccine Antibodies Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route |
| End point description: | Antibody titers were evaluated using the hemagglutination inhibition technique. |
| End point type | Secondary |
| End point timeframe: | Day 0 (pre-vaccination), Day 28 and Day 56 post-vaccination. |

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6–35 months) | IM Group (Age 6–35 months) |
|--|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| A/New Caledonia/20/99 (Day 0) | 9.77 (6.11 to 15.63) | 6.95 (4.32 to 11.18) | 6.3 (4.54 to 8.75) | 6.83 (4.21 to 11.09) |
| A/Wellington/1/2004 (Day 0) | 80 (39 to 164.2) | 113.1 (50.3 to 254.4) | 6.91 (4.66 to 10.24) | 10 (4.74 to 21.11) |
| B/Jiangsu/10/2003 (Day 0) | 5.95 (4.99 to 7.09) | 5.74 (4.74 to 6.96) | 5 (5 to 5) | 5 (5 to 5) |
| A/New Caledonia/20/99 (Day 28) | 40.5 (20.2 to 81) | 38.6 (19.6 to 75.7) | 19.3 (10.2 to 36.3) | 18.59 (9.56 to 36.15) |
| A/Wellington/1/2004 (Day 28) | 775 (321 to 1869) | 1428 (648 to 3145) | 57.3 (33 to 99.3) | 104.8 (44.7 to 245.5) |
| B/Jiangsu/10/2003 (Day 28) | 15.69 (8.73 to 28.22) | 16.97 (8.99 to 32.05) | 6.73 (5.46 to 8.3) | 7.07 (5.58 to 8.96) |
| A/New Caledonia/20/99 (Day 56) | 134.5 (79.9 to 226.5) | 169 (106 to 268) | 87 (48.3 to 156.6) | 115.1 (72.7 to 182.4) |
| A/Wellington/1/2004 (Day 56) | 1594 (984 to 2583) | 1328 (765 to 2303) | 261 (150 to 455) | 413 (240 to 710) |
| B/Jiangsu/10/2003 (Day 56) | 50.4 (32.1 to 79.1) | 58.6 (39.1 to 87.7) | 26.3 (16.9 to 40.9) | 23.8 (15.5 to 36.4) |

Statistical analyses

Secondary: Geometric Mean Titer Ratios (GMTRs) of Influenza vaccine Antibodies After Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|------------------------|---|
| End point title | Geometric Mean Titer Ratios (GMTRs) of Influenza vaccine Antibodies After Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route |
| End point description: | Antibodies were evaluated using the hemagglutination inhibition technique. Geometric mean titer ratio is the geometric mean of the individual post-vaccination/pre-vaccination titer of antibodies to three vaccine strains evaluated at Day 28/Day 0, Day 56/Day 0, and Day 56/Day 28. |
| End point type | Secondary |
| End point timeframe: | Day 0 (pre-vaccination) and Day 28 and Day 56 post-vaccination |

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6–35 months) | IM Group (Age 6–35 months) |
|--|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Titer ratios | | | | |
| geometric mean (confidence interval 95%) | | | | |
| A/New Caledonia/20/99 (Day 28/Day 0) | 4.14 (2.87 to 5.98) | 5.45 (3.89 to 7.65) | 3.01 (2.08 to 4.35) | 2.68 (1.87 to 3.83) |
| A/Wellington/1/2004 (Day 28/Day 0) | 10.41 (6.66 to 16.26) | 10.71 (6.37 to 18.02) | 8.1 (5.34 to 12.28) | 10.08 (6.55 to 15.5) |
| B/Jiangsu/10/2003 (Day 28/Day 0) | 2.64 (1.68 to 4.15) | 2.93 (1.82 to 4.73) | 1.35 (1.09 to 1.66) | 1.41 (1.12 to 1.79) |
| A/New Caledonia/20/99 (Day 56/Day 0) | 13.8 (10.3 to 18.5) | 24.3 (16.3 to 36) | 13.7 (8.58 to 21.88) | 16.9 (10.5 to 27) |
| A/Wellington/1/2004 (Day 56/Day 0) | 19.9 (13.1 to 30.4) | 12.62 (7.08 to 22.52) | 37.4 (21.6 to 64.6) | 41.3 (26.1 to 65.3) |
| B/Jiangsu/10/2003 (Day 56/Day 0) | 8.48 (5.91 to 12.15) | 10.2 (7.22 to 14.4) | 5.27 (3.39 to 8.18) | 4.76 (3.11 to 7.28) |
| A/New Caledonia/20/99 (Day 56/Day 28) | 3.32 (2.36 to 4.68) | 4.46 (2.88 to 6.92) | 4.32 (2.77 to 6.74) | 5.76 (3.75 to 8.85) |
| A/Wellington/1/2004 (Day 56/Day 28) | 1.95 (1.21 to 3.16) | 1.039 (0.712 to 1.517) | 4.55 (3.13 to 6.62) | 3.86 (2.8 to 5.31) |
| B/Jiangsu/10/2003 (Day 56/Day 28) | 3.21 (2.2 to 4.69) | 3.46 (2.13 to 5.62) | 3.66 (2.55 to 5.24) | 3.04 (2.39 to 3.87) |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Seroconversion or Significant Increase in Influenza Vaccine Antibodies Following Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|-----------------|---|
| End point title | Percentage of Subjects Achieving Seroconversion or Significant Increase in Influenza Vaccine Antibodies Following Vaccination |
|-----------------|---|

End point description:

Antibodies were evaluated using the hemagglutination inhibition technique. Seroconversion was defined as the following: for subjects with a pre-vaccination titer <10 (1/dil), post-injection titer ≥40 (1/dil) on Day 28 and Day 56 or significant increase and for subjects with a pre-vaccination titer ≥10 (1/dil), ≥ four-fold increase from pre- to post-injection titer on Day 28 and Day 56.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 0 (pre-vaccination), Day 28 and Day 56 post-vaccination

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6–35 months) | IM Group (Age 6–35 months) |
|---------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| A/New Caledonia/20/99 (Day 28/Day 0) | 33.3 | 36.8 | 17.9 | 21.1 |
| A/Wellington/1/2004 (Day 28/Day 0) | 75.9 | 84.2 | 53.6 | 88.9 |
| B/Jiangsu/10/2003 (Day 28/Day 0) | 20 | 21.1 | 0 | 0 |
| A/New Caledonia/20/99 (Day 56/Day 0) | 83.3 | 95 | 72.4 | 85 |
| A/Wellington/1/2004 (Day 56/Day 0) | 96.7 | 89.5 | 89.7 | 100 |
| B/Jiangsu/10/2003 (Day 56/Day 0) | 56.7 | 75 | 37.9 | 35 |
| A/New Caledonia/20/99 (Day 56/Day 28) | 50 | 73.7 | 55.6 | 78.9 |
| A/Wellington/1/2004 (Day 56/Day 28) | 34.5 | 11.1 | 66.7 | 73.7 |
| B/Jiangsu/10/2003 (Day 56/Day 28) | 33.3 | 47.4 | 33.3 | 21.1 |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Seroprotection Against Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route

| | |
|-----------------|---|
| End point title | Percentage of Subjects with Seroprotection Against Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine Administered by Either Intradermal or Intramuscular Route |
|-----------------|---|

End point description:

Antibodies were evaluated using the hemagglutination inhibition technique. Seroprotection was defined as antibody titers of ≥40 [1/dil] on Day 28 and Day 56.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 0 (pre-vaccination), Day 28 and Day 56 post-vaccination

| End point values | ID Group (Age 3–8 years) | IM Group (Age 3–8 years) | ID Group (Age 6-35 months) | IM Group (Age 6-35 months) |
|--------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 30 | 20 | 30 | 20 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| A/New Caledonia/20/99 (Day 0) | 23.3 | 10 | 6.7 | 5 |
| A/Wellington/1/2004 (Day 0) | 70 | 80 | 6.7 | 15.8 |
| B/Jiangsu/10/2003 (Day 0) | 0 | 0 | 0 | 0 |
| A/New Caledonia/20/99 (Day 28) | 40 | 36.8 | 17.9 | 21.1 |
| A/Wellington/1/2004 (Day 28) | 82.8 | 94.7 | 57.1 | 88.9 |
| B/Jiangsu/10/2003 (Day 28) | 20 | 21.1 | 0 | 0 |
| A/New Caledonia/20/99 (Day 56) | 86.7 | 95 | 72.4 | 95 |
| A/Wellington/1/2004 (Day 56) | 100 | 100 | 93.1 | 100 |
| B/Jiangsu/10/2003 (Day 56) | 56.7 | 75 | 37.9 | 35 |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse event data were collected from Day 0 (post-vaccination) up to Day 28 post-vaccination.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|-----|
| Dictionary version | 7.1 |
|--------------------|-----|

Reporting groups

| | |
|-----------------------|---------------------|
| Reporting group title | ID 9 µg (3–8 years) |
|-----------------------|---------------------|

Reporting group description:

Subjects received 2 intradermal doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28 in children aged 3–8 years.

| | |
|-----------------------|----------------------|
| Reporting group title | IM 15 µg (3–8 years) |
|-----------------------|----------------------|

Reporting group description:

Subjects received 2 intramuscular (IM) doses of the 15 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28 in children aged 3–8 years.

| | |
|-----------------------|-----------------------|
| Reporting group title | ID 9 µg (6–35 months) |
|-----------------------|-----------------------|

Reporting group description:

Subjects received 2 intradermal (ID) doses of the 9 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28 in infants aged 6–35 months.

| | |
|-----------------------|-------------------------|
| Reporting group title | IM 7.5 µg (6–35 months) |
|-----------------------|-------------------------|

Reporting group description:

Subjects received 2 intramuscular (IM) doses of the 7.5 µg formulation of inactivated, split-virion influenza vaccine administered on Day 0 and Day 28 in infants aged 6–35 months.

| Serious adverse events | ID 9 µg (3–8 years) | IM 15 µg (3–8 years) | ID 9 µg (6–35 months) |
|---|---------------------|----------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 0 / 30 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Infections and infestations | | | |
| Bronchiolitis | | | |
| alternative dictionary used: MedDRA 8.1 | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | IM 7.5 µg (6–35 months) | | |
|---|-------------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | | |
| number of deaths (all causes) | 0 | | |

| | | | |
|---|----------------|--|--|
| number of deaths resulting from adverse events | 0 | | |
| Infections and infestations | | | |
| Bronchiolitis | | | |
| alternative dictionary used: MedDRA 8.1 | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | ID 9 µg (3–8 years) | IM 15 µg (3–8 years) | ID 9 µg (6–35 months) |
|---|---------------------|----------------------|-----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 27 / 30 (90.00%) | 13 / 20 (65.00%) | 24 / 30 (80.00%) |
| Nervous system disorders | | | |
| Headache | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 2 / 20 (10.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Drowsiness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 13 / 30 (43.33%) |
| occurrences (all) | 0 | 0 | 13 |
| General disorders and administration site conditions | | | |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 20 (5.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 2 / 20 (10.00%) | 10 / 30 (33.33%) |
| occurrences (all) | 5 | 2 | 10 |
| Injection site pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 19 / 30 (63.33%) | 13 / 20 (65.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 19 | 13 | 0 |
| Injection site erythema | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|--|------------------|-----------------|------------------|
| subjects affected / exposed | 27 / 30 (90.00%) | 7 / 20 (35.00%) | 24 / 30 (80.00%) |
| occurrences (all) | 27 | 7 | 24 |
| Injection site edema | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 17 / 30 (56.67%) | 2 / 20 (10.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 17 | 2 | 0 |
| Injection site induration | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 14 / 30 (46.67%) | 6 / 20 (30.00%) | 16 / 30 (53.33%) |
| occurrences (all) | 14 | 6 | 16 |
| Injection site tenderness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 13 / 30 (43.33%) |
| occurrences (all) | 0 | 0 | 13 |
| Fever | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 4 / 20 (20.00%) | 8 / 30 (26.67%) |
| occurrences (all) | 1 | 4 | 8 |
| Malaise | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 4 / 20 (20.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 4 | 4 | 0 |
| Injection site swelling | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 7 / 30 (23.33%) |
| occurrences (all) | 0 | 0 | 7 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 2 / 20 (10.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 1 | 2 | 1 |
| Eye disorders | | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 1 / 20 (5.00%) | 2 / 30 (6.67%) |
| occurrences (all) | 3 | 1 | 2 |
| Gastrointestinal disorders | | | |

| | | | |
|---|----------------------|----------------------|------------------------|
| Abdominal pain subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 20 (5.00%) 1 | 0 / 30 (0.00%) 0 |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 2 / 30 (6.67%) 2 |
| Stomatitis subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Teething subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 4 / 30 (13.33%) 4 |
| Vomiting alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 4 / 30 (13.33%) 4 |
| Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 8 / 30 (26.67%) 8 | 6 / 20 (30.00%) 6 | 11 / 30 (36.67%) 11 |
| Pharyngolaryngeal pain subjects affected / exposed occurrences (all) | 1 / 30 (3.33%) 1 | 0 / 20 (0.00%) 0 | 1 / 30 (3.33%) 1 |
| Skin and subcutaneous tissue disorders Rash papular subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 1 / 20 (5.00%) 1 | 0 / 30 (0.00%) 0 |
| Psychiatric disorders Restlessness subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Abnormal crying alternative assessment type: Systematic | | | |

| | | | |
|---|-----------------|-----------------|------------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 16 / 30 (53.33%) |
| occurrences (all) | 0 | 0 | 16 |
| Irritability | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 20 (0.00%) | 19 / 30 (63.33%) |
| occurrences (all) | 0 | 0 | 19 |
| Musculoskeletal and connective tissue disorders | | | |
| Myalgia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 2 / 20 (10.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 1 / 20 (5.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Eye infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 1 / 20 (5.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 2 / 20 (10.00%) | 0 / 30 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 2 / 20 (10.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 4 | 2 | 1 |
| Otitis media | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 4 / 20 (20.00%) | 10 / 30 (33.33%) |
| occurrences (all) | 5 | 4 | 10 |
| Rhinitis | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 5 / 20 (25.00%) | 13 / 30 (43.33%) |
| occurrences (all) | 4 | 5 | 13 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 20 (5.00%) | 1 / 30 (3.33%) |
| occurrences (all) | 2 | 1 | 1 |
| Bronchiolitis | | | |

| | | | |
|---|---------------------|---------------------|------------------------|
| subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Pneumonia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 0 / 30 (0.00%) 0 |
| Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 2 / 30 (6.67%) 2 |
| Appetite lost alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 0 / 30 (0.00%) 0 | 0 / 20 (0.00%) 0 | 15 / 30 (50.00%) 15 |

| | | | |
|--|-------------------------|--|--|
| Non-serious adverse events | IM 7.5 µg (6-35 months) | | |
| Total subjects affected by non-serious adverse events subjects affected / exposed | 12 / 20 (60.00%) | | |
| Nervous system disorders Headache alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Drowsiness alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 3 / 20 (15.00%) 3 | | |
| General disorders and administration site conditions Injection site haemorrhage subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Pyrexia subjects affected / exposed occurrences (all) | 5 / 20 (25.00%) 5 | | |
| Injection site pain alternative assessment type: Systematic | | | |

| | | | |
|--|------------------|--|--|
| subjects affected / exposed | 0 / 20 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site erythema | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 5 / 20 (25.00%) | | |
| occurrences (all) | 5 | | |
| Injection site edema | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site induration | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 3 / 20 (15.00%) | | |
| occurrences (all) | 3 | | |
| Injection site tenderness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 4 / 20 (20.00%) | | |
| occurrences (all) | 4 | | |
| Fever | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 10 / 20 (50.00%) | | |
| occurrences (all) | 10 | | |
| Malaise | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site swelling | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 3 / 20 (15.00%) | | |
| occurrences (all) | 3 | | |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye disorders | | | |

| | | | |
|---|---|--|--|
| Conjunctivitis subjects affected / exposed occurrences (all) | 5 / 20 (25.00%) 5 | | |
| Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Stomatitis subjects affected / exposed occurrences (all) Teething subjects affected / exposed occurrences (all) Vomiting alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 0 / 20 (0.00%) 0 1 / 20 (5.00%) 1 0 / 20 (0.00%) 0 1 / 20 (5.00%) 1 | | |
| Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all) Cough subjects affected / exposed occurrences (all) Pharyngolaryngeal pain subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 4 / 20 (20.00%) 4 1 / 20 (5.00%) 1 | | |
| Skin and subcutaneous tissue disorders Rash papular subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Psychiatric disorders | | | |

| | | | |
|--|------------------------|--|--|
| Restlessness subjects affected / exposed occurrences (all) | 3 / 20 (15.00%) 3 | | |
| Abnormal crying alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 6 / 20 (30.00%) 6 | | |
| Irritability alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 12 / 20 (60.00%) 12 | | |
| Musculoskeletal and connective tissue disorders Myalgia alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Infections and infestations Bronchitis subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Eye infection subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Gastroenteritis subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 | | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | | |
| Otitis media subjects affected / exposed occurrences (all) | 7 / 20 (35.00%) 7 | | |
| Rhinitis subjects affected / exposed occurrences (all) | 12 / 20 (60.00%) 12 | | |
| Upper respiratory tract infection | | | |

| | | | |
|---|---------------------------------|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>4 / 20 (20.00%)</p> <p>4</p> | | |
| <p>Bronchiolitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 20 (5.00%)</p> <p>1</p> | | |
| <p>Pneumonia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 20 (5.00%)</p> <p>1</p> | | |
| <p>Metabolism and nutrition disorders</p> <p>Anorexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 20 (0.00%)</p> <p>0</p> | | |
| <p>Appetite lost</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>7 / 20 (35.00%)</p> <p>7</p> | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported